Olamkicept is under clinical development by Ferring International Center and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Olamkicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olamkicept overview

olamkicept (TJ-301) is under development for the treatment of inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The drug candidate is administered through intravenous route. The drug candidate is a recombinant soluble gp130 (sgp130) protein. It was also under development for rheumatoid arthritis (RA). It was also under development for the treatment of neuromyelitis optica, systemic sclerosis, castleman’s disease and system vasculitis

Ferring International Center overview

Ferring International Center (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women’s health, gastroenterology and urology. Ferring’s product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology, and orthopedics. Ferring’s products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.

For a complete picture of Olamkicept’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.